The company’s first therapeutic candidate is an IGF-methotrexate conjugate. Methotrexate has been covalently attached to an engineered form of the hormone insulin-like growth factor (IGF) which preferentially migrates to IGF receptor proteins which are overexpressed on certain cancer cells. Consequently, healthy cells receive relatively less drug.
The company’s second candidate drug acts by a different proprietary mechanism. It also targets a receptor that is greatly overexpressed on cancer cells and thereby selectively kills cancer cells. Human clinical trials of this are planned for ovarian cancer.